Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Nivolumab vs Placebo After Resection of Esophageal or Gastroesophageal Junction Cancer
2023-509360-24-00Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial in esophageal cancer and esophagogastric junction cancer comparing Adjuvant Opdivo with Adjuvant placebo (2 arms). Primary endpoint: Disease-free survival. Started Mar 2024; status: completed.
02
Drugs
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on 2023-509360-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509360-24-00.